Could an Alzheimer's drug slow Parkinson's? new trial aims to find out
NCT ID NCT07544953
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether lecanemab, a drug that clears amyloid plaques in Alzheimer's disease, can also help people with Parkinson's disease who have amyloid buildup in their brains. About 60 adults aged 50-90 with mild cognitive impairment or early dementia will receive lecanemab for 18 months. The main goal is to see if the drug reduces amyloid plaques and potentially slows Parkinson's progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yonsei University College of Medicine
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Planning ahead: could a simple program transform Parkinson's care?
- Sound waves vs. Parkinson's: can ultrasound calm tremors and stiffness?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can we outsmart Gaucher's hidden toll on lungs, bones, and brain?
- Could a brain disease change behavior years before diagnosis?